RSS

Pharmacovigilance Risk Assessment Committee (PRAC)

The European Medicines Agency (EMA) has concluded its review of Uptravi (selexipag) for the treatment of pulmonary arterial hypertension (PAH), confirming it can be continued to be used, according to the prescribing information. more

News